2025 MLS Nashville | ER Positive Breast Cancer Updates in 2025

Overview

Dr. Reid reported that ASCO trials are refining endocrine‑targeted therapy in HR‑positive/HER2‑negative MBC: Inavo 120 extended PFS and added 7 months OS with inavolisib + CDK4/6 inhibitor + fulvestrant in PIK3CA‑mutant disease; SERENA‑6 gave a 9.2‑month PFS edge when switching to camizestrant + CDK4/6 inhibition; VERITECH‑2 added 5 months PFS for ESR1‑mutant tumors on vepdegastrant; and FINER signaled PFS gains from patassertib + fulvestrant in patients with PIK3CA‑pathway alterations.

Target Audience

Physicians
Nurses
Pharmacists
Physician Associates

This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.

Faculty

Sonya A. Reid, MD

Date of Release

June 24th, 2025

Content

ER Positive Breast Cancer Updates in 2025

Related Material

No courses found

Explore More